JPWO2020132327A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020132327A5 JPWO2020132327A5 JP2021536031A JP2021536031A JPWO2020132327A5 JP WO2020132327 A5 JPWO2020132327 A5 JP WO2020132327A5 JP 2021536031 A JP2021536031 A JP 2021536031A JP 2021536031 A JP2021536031 A JP 2021536031A JP WO2020132327 A5 JPWO2020132327 A5 JP WO2020132327A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- pharmaceutical composition
- mage
- seq
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 53
- 239000000427 antigen Substances 0.000 claims description 52
- 102000036639 antigens Human genes 0.000 claims description 52
- 108091007433 antigens Proteins 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 42
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 29
- 210000004027 cell Anatomy 0.000 claims description 23
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- -1 MN-CA IX Proteins 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 12
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 11
- 102100023635 Alpha-fetoprotein Human genes 0.000 claims description 10
- 101150026580 CD5 gene Proteins 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 9
- 102100038358 Prostate-specific antigen Human genes 0.000 claims description 9
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 6
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 6
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 6
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
- 101150047061 tag-72 gene Proteins 0.000 claims description 6
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims description 3
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims description 3
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 claims description 3
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 claims description 3
- 102100030840 AT-rich interactive domain-containing protein 4B Human genes 0.000 claims description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 101710145634 Antigen 1 Proteins 0.000 claims description 3
- 102100024003 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 Human genes 0.000 claims description 3
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 3
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims description 3
- 102000015735 Beta-catenin Human genes 0.000 claims description 3
- 108060000903 Beta-catenin Proteins 0.000 claims description 3
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 3
- 102100039510 Cancer/testis antigen 2 Human genes 0.000 claims description 3
- 102000013392 Carboxylesterase Human genes 0.000 claims description 3
- 108010051152 Carboxylesterase Proteins 0.000 claims description 3
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 3
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims description 3
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 claims description 3
- 108010072210 Cyclophilin C Proteins 0.000 claims description 3
- 101150029707 ERBB2 gene Proteins 0.000 claims description 3
- 102000006396 Ephrin-B2 Human genes 0.000 claims description 3
- 108010044090 Ephrin-B2 Proteins 0.000 claims description 3
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 3
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 3
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 claims description 3
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 claims description 3
- 102100039717 G antigen 1 Human genes 0.000 claims description 3
- 101710113436 GTPase KRas Proteins 0.000 claims description 3
- 102100040510 Galectin-3-binding protein Human genes 0.000 claims description 3
- 101710197901 Galectin-3-binding protein Proteins 0.000 claims description 3
- 208000032612 Glial tumor Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 3
- 101000792935 Homo sapiens AT-rich interactive domain-containing protein 4B Proteins 0.000 claims description 3
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims description 3
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 3
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 3
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 3
- 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 claims description 3
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims description 3
- 101000886137 Homo sapiens G antigen 1 Proteins 0.000 claims description 3
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 3
- 101001014223 Homo sapiens MAPK/MAK/MRK overlapping kinase Proteins 0.000 claims description 3
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 claims description 3
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 3
- 101001062222 Homo sapiens Receptor-binding cancer antigen expressed on SiSo cells Proteins 0.000 claims description 3
- 101000973629 Homo sapiens Ribosome quality control complex subunit NEMF Proteins 0.000 claims description 3
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 claims description 3
- 101000671653 Homo sapiens U3 small nucleolar RNA-associated protein 14 homolog A Proteins 0.000 claims description 3
- 108010031794 IGF Type 1 Receptor Proteins 0.000 claims description 3
- 101710123134 Ice-binding protein Proteins 0.000 claims description 3
- 101710082837 Ice-structuring protein Proteins 0.000 claims description 3
- 102000004877 Insulin Human genes 0.000 claims description 3
- 108090001061 Insulin Proteins 0.000 claims description 3
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims description 3
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims description 3
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims description 3
- 108010030506 Integrin alpha6beta4 Proteins 0.000 claims description 3
- 102100034872 Kallikrein-4 Human genes 0.000 claims description 3
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims description 3
- 101710093778 L-dopachrome tautomerase Proteins 0.000 claims description 3
- 108010028275 Leukocyte Elastase Proteins 0.000 claims description 3
- 102100031520 MAPK/MAK/MRK overlapping kinase Human genes 0.000 claims description 3
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 3
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 claims description 3
- 102100025136 Macrosialin Human genes 0.000 claims description 3
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 3
- 102000003735 Mesothelin Human genes 0.000 claims description 3
- 108090000015 Mesothelin Proteins 0.000 claims description 3
- 102100033174 Neutrophil elastase Human genes 0.000 claims description 3
- 102100024968 Peptidyl-prolyl cis-trans isomerase C Human genes 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 3
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 3
- 102100029165 Receptor-binding cancer antigen expressed on SiSo cells Human genes 0.000 claims description 3
- 102100022213 Ribosome quality control complex subunit NEMF Human genes 0.000 claims description 3
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 claims description 3
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 claims description 3
- 108010002687 Survivin Proteins 0.000 claims description 3
- 208000000389 T-cell leukemia Diseases 0.000 claims description 3
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims description 3
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 3
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 3
- 101150031162 TM4SF1 gene Proteins 0.000 claims description 3
- 108010017842 Telomerase Proteins 0.000 claims description 3
- 102000009843 Thyroglobulin Human genes 0.000 claims description 3
- 108010034949 Thyroglobulin Proteins 0.000 claims description 3
- 102100034902 Transmembrane 4 L6 family member 1 Human genes 0.000 claims description 3
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 claims description 3
- 101710107540 Type-2 ice-structuring protein Proteins 0.000 claims description 3
- 102000003425 Tyrosinase Human genes 0.000 claims description 3
- 108060008724 Tyrosinase Proteins 0.000 claims description 3
- 102100040099 U3 small nucleolar RNA-associated protein 14 homolog A Human genes 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 229940084986 human chorionic gonadotropin Drugs 0.000 claims description 3
- 229940125396 insulin Drugs 0.000 claims description 3
- 230000000968 intestinal effect Effects 0.000 claims description 3
- 108010024383 kallikrein 4 Proteins 0.000 claims description 3
- 238000012737 microarray-based gene expression Methods 0.000 claims description 3
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 3
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 3
- 108040000983 polyphosphate:AMP phosphotransferase activity proteins Proteins 0.000 claims description 3
- 229960002175 thyroglobulin Drugs 0.000 claims description 3
- 102100037253 Solute carrier family 45 member 3 Human genes 0.000 claims description 2
- 108010079891 prostein Proteins 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 description 20
- 108020004707 nucleic acids Proteins 0.000 description 16
- 102000039446 nucleic acids Human genes 0.000 description 16
- 108091033409 CRISPR Proteins 0.000 description 10
- 230000003834 intracellular effect Effects 0.000 description 10
- 238000010354 CRISPR gene editing Methods 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000008685 targeting Effects 0.000 description 3
- 101710163573 5-hydroxyisourate hydrolase Proteins 0.000 description 2
- 101150069832 CD2 gene Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 108010052919 Hydroxyethylthiazole kinase Proteins 0.000 description 2
- 108010027436 Hydroxymethylpyrimidine kinase Proteins 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 108091027544 Subgenomic mRNA Proteins 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 108010020589 trehalose-6-phosphate synthase Proteins 0.000 description 2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024046429A JP7843056B2 (ja) | 2018-12-19 | 2024-03-22 | Ｔ細胞リンパ腫およびｔ細胞白血病に対するｃｄ２／５／７ノックアウト抗ｃｄ２／５／７キメラ抗原受容体ｔ細胞の使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782131P | 2018-12-19 | 2018-12-19 | |
| US62/782,131 | 2018-12-19 | ||
| PCT/US2019/067613 WO2020132327A1 (en) | 2018-12-19 | 2019-12-19 | Use of cd2/5/7 knock-out anti-cd2/5/7 chimeric antigen receptor t cells against t cell lymphomas and leukemias |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024046429A Division JP7843056B2 (ja) | 2018-12-19 | 2024-03-22 | Ｔ細胞リンパ腫およびｔ細胞白血病に対するｃｄ２／５／７ノックアウト抗ｃｄ２／５／７キメラ抗原受容体ｔ細胞の使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022515194A JP2022515194A (ja) | 2022-02-17 |
| JPWO2020132327A5 true JPWO2020132327A5 (https=) | 2022-12-26 |
| JP2022515194A5 JP2022515194A5 (https=) | 2022-12-26 |
| JP7620374B2 JP7620374B2 (ja) | 2025-01-23 |
Family
ID=71102914
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021536031A Active JP7620374B2 (ja) | 2018-12-19 | 2019-12-19 | Ｔ細胞リンパ腫およびｔ細胞白血病に対するｃｄ２／５／７ノックアウト抗ｃｄ２／５／７キメラ抗原受容体ｔ細胞の使用 |
| JP2024046429A Active JP7843056B2 (ja) | 2018-12-19 | 2024-03-22 | Ｔ細胞リンパ腫およびｔ細胞白血病に対するｃｄ２／５／７ノックアウト抗ｃｄ２／５／７キメラ抗原受容体ｔ細胞の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024046429A Active JP7843056B2 (ja) | 2018-12-19 | 2024-03-22 | Ｔ細胞リンパ腫およびｔ細胞白血病に対するｃｄ２／５／７ノックアウト抗ｃｄ２／５／７キメラ抗原受容体ｔ細胞の使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11673964B2 (https=) |
| EP (1) | EP3898692A4 (https=) |
| JP (2) | JP7620374B2 (https=) |
| KR (1) | KR20220002859A (https=) |
| CN (2) | CN113454117B (https=) |
| AU (1) | AU2019404302A1 (https=) |
| CA (1) | CA3124467A1 (https=) |
| IL (1) | IL284196A (https=) |
| MX (1) | MX2021007547A (https=) |
| SG (1) | SG11202106699VA (https=) |
| WO (1) | WO2020132327A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2014010185A (es) * | 2012-02-22 | 2014-11-14 | Univ Pennsylvania | Uso de dominio de señalizacion cd2 en receptores de antigeno quimericos de segunda generacion. |
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| WO2020168122A1 (en) | 2019-02-13 | 2020-08-20 | Beam Therapeutics Inc. | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| EP4034138A4 (en) | 2019-09-27 | 2024-07-31 | Beam Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| WO2022061115A1 (en) * | 2020-09-18 | 2022-03-24 | Vor Biopharma Inc. | Compositions and methods for cd7 modification |
| AU2021347359A1 (en) * | 2020-09-25 | 2023-05-18 | Beam Therapeutics Inc. | Fratricide resistant modified immune cells and methods of using the same |
| CN116568709A (zh) * | 2020-11-01 | 2023-08-08 | 南京驯鹿生物技术股份有限公司 | 靶向cd5的全人源抗体、全人源嵌合抗原受体（car）及其应用 |
| CA3197423A1 (en) | 2020-11-04 | 2022-05-12 | Daniel Getts | Engineered chimeric fusion protein compositions and methods of use thereof |
| EP4279515A4 (en) * | 2021-01-12 | 2025-02-19 | Nanjing Iaso Biotechnology Co., Ltd. | Fully human single-domain tandem chimeric antigen receptor (car) targeting cd5, and use thereof |
| CA3207861A1 (en) * | 2021-02-11 | 2022-08-18 | Carl H. June | Ccr4-targeting chimeric antigen receptor cell therapy |
| CN115044617B (zh) * | 2021-03-08 | 2024-08-13 | 河北森朗生物科技有限公司 | Car t细胞的制备方法、car t细胞及其应用 |
| EP4308133A4 (en) | 2021-03-17 | 2025-01-22 | Myeloid Therapeutics, Inc. | MANIPULATED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF |
| AU2022272235A1 (en) | 2021-05-11 | 2023-12-21 | Create Medicines, Inc. | Methods and compositions for genomic integration |
| CN115989244A (zh) * | 2021-08-06 | 2023-04-18 | 上海驯鹿生物技术有限公司 | Cd5和cd7双靶点的全人源嵌合抗原受体(car)及其应用 |
| CA3240846A1 (en) * | 2021-12-14 | 2023-06-22 | The Trustees Of The University Of Pennsylvania | Cd5 modified cells comprising chimeric antigen receptors (cars) for treatment of solid tumors |
| CN114645022B (zh) * | 2022-05-13 | 2022-09-02 | 首都医科大学宣武医院 | 靶向CD5的CAR-γ δ T细胞及其制备方法与应用 |
| CN117431217A (zh) * | 2022-07-12 | 2024-01-23 | 上海驯鹿生物技术有限公司 | 表达靶向cd5的嵌合抗原受体(car)的细胞及其应用 |
| KR102869461B1 (ko) * | 2022-10-05 | 2025-10-17 | 주식회사 지씨셀 | Cd5를 표적하는 키메라 항원 수용체 및 이를 발현하는 면역세포 |
| KR20260051108A (ko) * | 2023-05-23 | 2026-04-15 | 비토리아 바이오테라퓨틱스, 인코포레이티드. | Cd5 유전자좌 영역에 삽입된 이종성 핵산 분자를 포함하는 유전자 변형 세포 |
| EP4719467A2 (en) * | 2023-05-31 | 2026-04-08 | Vittoria Biotherapeutics, Inc. | Methods of manufacturing t cells |
| CN119529071B (zh) * | 2023-08-28 | 2025-11-18 | 东莞市朋志生物科技有限公司 | 一种抗登革病毒或其ns1蛋白的抗体及其应用 |
| WO2025122896A1 (en) * | 2023-12-08 | 2025-06-12 | The Trustees Of The University Of Pennsylvania | Cd5 modified cells comprising heterologous tcrs and methods of using the same |
| CN118891290A (zh) * | 2024-04-12 | 2024-11-01 | 科济生物医药（上海）有限公司 | 细胞免疫疗法的组合物和方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5951983A (en) | 1993-03-05 | 1999-09-14 | Universite Catholique De Louvain | Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies |
| MX2011000970A (es) | 2008-08-29 | 2011-03-15 | Symphogen As | Anticuerpos anti-cd5. |
| US11047010B2 (en) * | 2014-02-06 | 2021-06-29 | Immunexpress Pty Ltd | Biomarker signature method, and apparatus and kits thereof |
| JP7237449B2 (ja) | 2015-02-27 | 2023-03-13 | アイセル・ジーン・セラピューティクス・エルエルシー | 血液系腫瘍を標的としたキメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| WO2017112877A1 (en) | 2015-12-22 | 2017-06-29 | Icell Gene Therapeutics, Llc | Chimeric antigen receptors and enhancement of anti-tumor activity |
| WO2017172981A2 (en) * | 2016-03-29 | 2017-10-05 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| EP3448874A4 (en) * | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| CN110352068A (zh) | 2016-12-02 | 2019-10-18 | 南加利福尼亚大学 | 合成的免疫受体及其使用方法 |
| WO2018156180A1 (en) * | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| EP4414380A3 (en) * | 2017-03-31 | 2024-12-04 | Cellectis SA | Universal anti-cd22 chimeric antigen receptor engineered immune cells |
| CA3065126A1 (en) * | 2017-06-01 | 2018-12-06 | Innovative Cellular Therapeutics CO., LTD. | Chimeric antigen receptor cell preparation and uses thereof |
-
2019
- 2019-12-19 WO PCT/US2019/067613 patent/WO2020132327A1/en not_active Ceased
- 2019-12-19 MX MX2021007547A patent/MX2021007547A/es unknown
- 2019-12-19 EP EP19898610.1A patent/EP3898692A4/en active Pending
- 2019-12-19 CA CA3124467A patent/CA3124467A1/en active Pending
- 2019-12-19 CN CN201980092281.9A patent/CN113454117B/zh active Active
- 2019-12-19 AU AU2019404302A patent/AU2019404302A1/en active Pending
- 2019-12-19 CN CN202510805788.1A patent/CN121059792A/zh active Pending
- 2019-12-19 JP JP2021536031A patent/JP7620374B2/ja active Active
- 2019-12-19 US US17/416,365 patent/US11673964B2/en active Active
- 2019-12-19 KR KR1020217022614A patent/KR20220002859A/ko active Pending
- 2019-12-19 SG SG11202106699VA patent/SG11202106699VA/en unknown
-
2021
- 2021-06-20 IL IL284196A patent/IL284196A/en unknown
-
2023
- 2023-04-21 US US18/304,843 patent/US20230331864A1/en active Pending
-
2024
- 2024-03-22 JP JP2024046429A patent/JP7843056B2/ja active Active
- 2024-03-28 US US18/620,748 patent/US12227588B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020132327A5 (https=) | ||
| JP2018518978A5 (https=) | ||
| JP2021035366A5 (https=) | ||
| JP2020504628A5 (https=) | ||
| JP7221213B2 (ja) | 多官能性タンパク質 | |
| US12590148B2 (en) | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy | |
| ES2813437T3 (es) | Métodos para mejorar la eficiencia de la transducción vectorial en linfocitos T | |
| AU2014240083B2 (en) | Modified T lymphocytes | |
| HRP20221167T1 (hr) | Čestice arenavirusa kao cjepiva protiv raka | |
| JP2026053384A (ja) | チェックポイント分子を標的とするｄｎａモノクロナール抗体 | |
| Rugo et al. | Abstract GS3-01: additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer | |
| JP2010533649A5 (https=) | ||
| WO2022188764A1 (zh) | 一种低表达cd7的nk细胞制备方法 | |
| US20250228926A1 (en) | Rna vaccine lipid nanoparticles | |
| CN110392736A (zh) | 遗传修饰的反抑细胞及其在免疫治疗中的用途 | |
| JP2025106247A (ja) | エンジニアリングされた免疫細胞 | |
| US20200283525A1 (en) | Dna monoclonal antibodies targeting ctla-4 for the treatment and prevention of cancer | |
| US20240197910A1 (en) | Immunostimulatory toll-like receptor agonist-nanoparticle for cancer immunotherapy | |
| Pangarsa et al. | Covid-19 vaccination in patients with cancer: Position paper from the indonesian society of hematology and medical oncology (ishmo) of semarang | |
| US20230149540A1 (en) | Vaccine platform for the induction of systemic immune responses | |
| US20250257131A1 (en) | Bispecific T Cell Engagers Targeting Tumor Antigens | |
| US20250250348A1 (en) | Bispecific Binding Molecules That Target FSHR and CD3 | |
| EP4178548A1 (en) | Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)m ethyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same | |
| AU2017204617B2 (en) | Chimeric antigen receptors | |
| CN106478823B (zh) | Her1靶向性的嵌合抗原受体和nkt细胞及其制法和应用 |